超声可识别纳武利尤单抗治疗中的假性进展
两例转移性黑色素瘤患者接受纳武利尤单抗治疗后,超声显示目标病灶在40-50天后尺寸增大约10%,但瘤内血流在50天内减少约20%,血流减少后约100天肿瘤开始缩小。对比增强CT未能发现肿瘤大小与血流的关系。提示超声可能有助于鉴别假性进展与真性进展。
要点
- 免疫检查点抑制剂治疗中超声可评估瘤内血流变化以辅助鉴别假性进展。
- 病灶尺寸增大但血流减少可能提示假性进展而非真性进展。
- 对比增强CT未能显示肿瘤大小与血流的关系。
核心结论
- 超声可能有助于鉴别免疫检查点抑制剂治疗中的假性进展与真性进展。
研究设计与样本
- 两例接受纳武利尤单抗治疗的转移性黑色素瘤病例,对体表可及的目标病灶进行超声检查。
主要发现
- 两例中超声均显示纳武利尤单抗给药40-50天后病灶尺寸增大约10%,而50天内瘤内血流减少约20%。
- 超声检测到血流减少后约100天,肿瘤开始缩小。
- 对比增强CT未能检测到肿瘤大小与肿瘤血流之间的关联。
临床怎么用
- 对免疫检查点抑制剂治疗患者,可用超声评估目标病灶血流变化辅助判断假性进展。
- 避免因误判真性进展而进行不必要的治疗更改。
局限性
- 仅基于两例病例,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
'Pseudoprogression' is often seen in patients with melanomas who are treated with immune checkpoint inhibitors such as nivolumab or ipilimumab. We sometimes evaluate metastatic lesions by imaging tests such as computed tomography (CT) or positron emission tomography-CT. 'Pseudoprogression' usually occurs upon the initial administration, which may make it difficult for the physician to determine the disease condition. In our two cases of metastatic melanoma treated with nivolumab (antiprogrammed cell death-1 antibody), we examined the ultrasonography (US) of target lesions that could be accessed from the body surface, such as those of the regional lymph node or subcutaneous metastasis. In both cases, the US revealed a lesion approximately 10% greater in size after 40-50 days of nivolumab administration, even though the blood flow inside the tumour was reduced by about 20% within 50 days. From about 100 days after blood flow reduction was detected by US, the tumours began to decrease in size. However, contrast CT was unable to detect the association between tumour size and tumour blood flow. The present cases suggest that US could be a powerful tool for differentiating between 'pseudoprogression' and real progressive disease in patients treated with cancer immunotherapies such as those involving immune checkpoint inhibitors. The misdiagnosis of progressive disease can lead to unnecessary alterations to the current treatment. Therefore, the US findings in our study could be clinically useful and educational for physicians.
引用
- Imafuku K, Hata H, Kitamura S, et al. Ultrasonographic findings can identify 'pseudoprogression' under nivolumab therapy. Br J Dermatol. 2017. PMID: 27873302. doi:10.1111/bjd.15198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。